1.鹽酸可樂(lè)定緩釋片   廠家：力品藥業(yè)（廈門(mén)）股份有限公司  需要這個(gè)品種2022最新的藥品說(shuō)明書(shū)2.脂肪乳氨基酸（17）葡萄糖（19%）注射液    廠家：Fresenius Kabi AB  需要這個(gè)品種2022最新的藥品說(shuō)明書(shū)3.鹽酸莫西沙星滴眼液   廠家：沈陽(yáng)興齊眼藥股份有限公司 和 北京匯恩蘭德制藥有限公司  需要這個(gè)品種2022最新的藥品說(shuō)明書(shū)4.復(fù)方氨基酸注射液（20AA）   廠家：內(nèi)蒙古白醫(yī)制藥股份有限公司    需要這個(gè)品種2022最新的藥品說(shuō)明書(shū)5.利丙雙卡因乳膏，廠家：四川海思科制藥有限公司，要一致性過(guò)評(píng)的說(shuō)明書(shū)（有一致性評(píng)價(jià)標(biāo)志）6.利丙雙卡因乳膏，廠家：珠海萊奇生物科技有限公司，要一致性過(guò)評(píng)的說(shuō)明書(shū)（有一致性評(píng)價(jià)標(biāo)志）7.小兒復(fù)方氨基酸注射液(18AA-Ⅱ)，需要這個(gè)品種2020最新的藥品說(shuō)明書(shū)備注：上述說(shuō)明書(shū)書(shū)均需要清晰附件類(lèi)型。   [更多]

1懸賞的藥品注冊(cè)信息為2013年1月1日之后不批準(zhǔn)、退審的藥品注冊(cè)信息,以及補(bǔ)充藥品注冊(cè)信息 2必須提供完整注冊(cè)信息,以附件形式提交 3核實(shí)后如果正確,每個(gè)藥品注冊(cè)信息獎(jiǎng)勵(lì)100元 4投稿時(shí)請(qǐng)隱藏提交 5請(qǐng)勿在百度上直接搜索 6需是未收集的數(shù)據(jù)   [更多]

標(biāo)題信息: 1、 Jian YIN, Xiao Bo YANG, Zai Xin CHEN, Yi Huan ZHANG.Total Synthesis of (-)-Tetrahydrolipstatin by the Tandem Mukaiyama-aldol Lactonization Chinese Chemical Letters Vol.16, No.11, pp 1448-1450, 2005 2.、Bidard, F. C. & Pierga, J. Y. Clinical utility of circulating tumor cells in metastatic breast cancer. J. Clin. Oncol. 33, 1622 (2015). 3、Schramm, A. et al. The DETECT Study Program: personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs). ASCO Meet. Abstr. 33, TPS11109 (2015). 4、.Ignatiadis, M. et al. Abstract OT1-2-02: trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC). Cancer Res. 75, OT1-2–02 (2015). 5、Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. 備注：將符合標(biāo)題的PDF上傳，先到先得   [更多]

搜集2020.10-2020.12藥監(jiān)局等機(jī)構(gòu)官方公布的法規(guī)文件。 具體要求可私聊。   [更多]

1、PDF文件，要求：無(wú)水印，完整，清晰，來(lái)源可靠（非討論稿等），非網(wǎng)上百度所得，盡量為最新版的炮制規(guī)范。 2、45元一個(gè)省份的中藥飲片炮制規(guī)范，目前總共需要10個(gè)省份的資料。 3、需要炮制規(guī)范的省份目錄：山西省、湖北省、湖南省、海南省、陜西省、青海省、內(nèi)蒙古自治區(qū)、西藏自治區(qū)、寧夏回族自治區(qū)、新疆維吾爾自治區(qū)   [更多]

《湖南省中藥飲片炮制規(guī)范》（2021年版）電子版全件一份   [更多]

1. （7）G G, Shapiro ，Effects of albuterol and procaterol on exercise-induced asthma，Annals of allergy 65(4):273-6 . November 1990. 2. G G, Shapiro ，Effects of albuterol and procaterol on exercise-induced asthma，Annals of allergy 65(4):273-6 . November 1990. 3. 1.NAFLD in Asia—as common and important as in the West 4. Fundamentals of the chemotherapy of trichomoniasis and amebiasis with ornidazole 5. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism 6. [1] Cheesman EH, Blanchette MA, Ganey MV, Maheu LI, Miller SJ, Watson AD. Technetium-99m ECD: ester-derivatizeddiamine-dithiolTc complexesforimaging brain perfusion [Abstract].J Nucl Med, 1988, 29:788. 7. [2] Demonceau G, Leveille J, De Roo M et al. Comparison of Tc-99m-ECD and Tc-99m-HMPAO: First human resulte[Abstract]. J Nucl Med, 1988, 29(5): 747. 8. standards of medical care in diabetic peripheral neuropathy 9. 2017年中藥飲片行業(yè)發(fā)展藍(lán)皮書(shū)   [更多]

1.脂肪乳氨基酸(17)葡萄糖(19%)注射液，廠家：四川科倫藥業(yè)股份有限公司，批準(zhǔn)文號(hào)：國(guó)藥準(zhǔn)字H20205000，規(guī)格：1026ml［脂肪乳注射液（20％）200ml；復(fù)方氨基酸注射液（17）（11％）300ml；葡萄糖注射液（19％）526ml]2.克林霉素磷酸酯注射液、湖南科倫制藥有限公司3.奧利司他膠囊、植恩生物技術(shù)股份有限公司（2024年最新版說(shuō)明書(shū)）4.腹膜透析液（乳酸鹽-G4.25%），規(guī)格：含4.25%葡萄糖(5L/袋)，企業(yè)：廣州百特醫(yī)療用品有限公司5.琥珀酸曲格列汀片、廠家：四川科倫藥業(yè)。要求：內(nèi)容清晰、最新版附件說(shuō)明書(shū)   [更多]

文獻(xiàn)標(biāo)題及相關(guān)內(nèi)容 1、Temperature-sensitive liposomes for codelivery of tamoxifen and imatinib for synergistic breast cancer treatment（doi: 10.1080/08982104.2018.1502315） 2、 Hyaluronated Imatinib Liposomes with Hybrid approach to Target CD44 and P-gp Overexpressing MDR Cancer: An In-vitro, In-vivo and Mechanistic Investigation（doi: 10.1080/1061186X.2018.1497039） 3、Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells. Artif Cells Nanomed Biotechnol（doi: 10.1080/21691401.2016.1202257） 4、Man-Fung Yuen, MD, PhD.Hepatocellular Carcinoma: A Global Perspective.2018 ASCO 5、CS-386の安全性試験実験動(dòng)物に対する急性,亜急性ならびに慢性毒性試験(原著論文) 増?zhí)镌?(三共), 木村邦男 , 山下和男 , 金丸三記雄 , 松沼尚央 三共研究所年報(bào) (1341-741X)30巻 Page175-192(1978.12） 6、吉田 勇 ほか Jpn J Antibiot, 63(6),457-479,2010 備注：提供PDF原件電子檔，先到先得   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]